Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909395 | 0.94 | CNR1 (0.49) | CNR1OPRL1KCNH2CNR2 | |
| SCHEMBL1376522 | 0.90 | OPRL1 (0.55) | CNR1OPRL1KCNH2CNR2 | |
| SCHEMBL908989 | 0.88 | CNR1 (0.51) | CNR1OPRL1KCNH2MALT1 | |
| SCHEMBL5621822 | 0.87 | CNR1 (0.49) | CNR1OPRL1KCNH2CNR2MALT1 | |
| SCHEMBL2769225 | 0.86 | OPRL1 (0.50) | CNR1OPRL1KCNH2 | |
| SCHEMBL907994 | 0.83 | CNR1 (0.44) | CNR1 | |
| SCHEMBL1377828 | 0.83 | OPRL1 (0.46) | CNR1OPRL1KCNH2 | |
| SCHEMBL909029 | 0.83 | CNR1 (0.47) | CNR1OPRL1KCNH2CNR2 | |
| SCHEMBL909140 | 0.82 | CNR1 (0.47) | CNR1OPRL1KCNH2CNR2 | |
| SCHEMBL909208 | 0.81 | CNR1 (0.44) | CNR1OPRL1KCNH2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875646-B2 | Cannabinoid receptor antagonist; N-{[5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]methyl}-3-cyanobenzenesulfonamide; psychiatric disorder, substance dependence and withdrawal disorder, cognitive disorder, ADD, neurodegenerative diseases, pain, eating disorders, dyslipidemia, ulcer | SANOFI-AVENTIS (FR) | 2011-01-25 | — | — | US | claimed |
| EP-1878723-B1 | N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide derivatives antagonists of the CB1 cannabinoids receptors | SANOFI AVENTIS (FR) | 2010-05-26 | — | — | EP | claimed |
| US-20080070962-A1 | DERIVATIVES OF N-[(1,5-DIPHENYL-1H-PYRAZOL-3-YL)METHYL] SULFONAMIDE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-03-20 | — | — | US | claimed |
| EP-1878723-A1 | N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide derivatives antagonists of the CB1 cannabinoids receptors | Sanofi-Aventis (FR) | 2008-01-16 | — | — | EP | claimed |
| US-7875646-B2 | Cannabinoid receptor antagonist; N-{[5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]methyl}-3-cyanobenzenesulfonamide; psychiatric disorder, substance dependence and withdrawal disorder, cognitive disorder, ADD, neurodegenerative diseases, pain, eating disorders, dyslipidemia, ulcer | SANOFI-AVENTIS (FR) | 2011-01-25 | — | — | US | disclosed |
| EP-1878723-B1 | N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide derivatives antagonists of the CB1 cannabinoids receptors | SANOFI AVENTIS (FR) | 2010-05-26 | — | — | EP | disclosed |
| US-20080070962-A1 | DERIVATIVES OF N-[(1,5-DIPHENYL-1H-PYRAZOL-3-YL)METHYL] SULFONAMIDE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-03-20 | — | — | US | disclosed |
| EP-1878723-A1 | N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide derivatives antagonists of the CB1 cannabinoids receptors | Sanofi-Aventis (FR) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070962-A1 | DERIVATIVES OF N-[(1,5-DIPHENYL-1H-PYRAZOL-3-YL)METHYL] SULFONAMIDE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | PRMT5, PRMT3, PRMT1 | CNR1 93/4885OPRL1 2208/4885KCNH2 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.